Ongoing attempts with immune-based therapeutic interventions targeting FAP in areas of active tissue remodeling suggest that specific interventions aiming at subpopulations of VSMCs expressing FAP in coronary disease may be useful in the future, and experimental models are currently being developed [23]. This evidence concerns the gene FAP and coronary artery disorder.